Table 3 Demographic and clinical characteristics of < 75% responders and ≥ 75% responders in patients with high-frequency episodic (HFEM) or chronic migraine (CM)
Number (%) or mean ± SD | Number (%) or mean ± SD | |||||
|---|---|---|---|---|---|---|
HFEM | CM | |||||
< 75% responders | ≥75% responders | p-value | < 75% responders | ≥75% responders | p-value | |
Patients | 144 (69.2%) | 64 (30.8%) | 458 (69.8%) | 198 (30.2%) | ||
Age, yrs | 47.5 ± 11.2 | 49.8 ± 10.5 | 0.167 | 47.6 ± 11.7 | 47.9 ± 11.5 | 0.815 |
Females | 133 (78.4) | 45 (70.3) | 0.204 | 367 (80.1) | 150 (75.8) | 0.208 |
BMI | 22.8 ± 2.5 | 22.6 ± 3.1 | 0.789 | 23.5 ± 4.1 | 23.0 ± 3.7 | 0.173 |
BMI class | 0.457 | 0.848 | ||||
Underweight | 5 (4.3) | 3 (5.5) | 24 (6.1) | 10 (6.0) | ||
Normal | 88 (75.2) | 38 (69.1) | 261 (66.6) | 117 (70.1) | ||
Overweight | 24 (20.5) | 13 (23.6) | 83 (21.2) | 32 (19.2) | ||
Obesity | 0 | 1 (1.8) | 24 (6.1) | 8 (4.8) | ||
Disease duration, yrs | 29.5 ± 11.9 | 29.6 ± 13.1 | 0.932 | 30.2 ± 12.8 | 31.3 ± 12.6 | 0.321 |
MMDs/MHDs at baseline | 10.8 ± 2.1 | 11.0 ± 1.8 | 0.713 | 24.0 ± 5.8 | 23.3 ± 5.7 | 0.180 |
MOH | – | – | – | 400 (70.0) | 171 (30.0) | 0.733 |
MOH duration, yrs | – | – | – | 9.5 ± 9.8 | 8.0 ± 6.3 | 0.073 |
Monthly analgesic intake at baseline | 12.6 ± 6.0 | 12.7 ± 4.1 | 0.926 | 28.0 ± 24.6 | 26.1 ± 18.6 | 0.333 |
NRS score | 7.5 ± 1.5 | 7.6 ± 1.4 | 0.751 | 7.8 ± 1.3 | 7.7 ± 1.2 | 0.314 |
UP | 77 (55.8) | 40 (63.5) | 0.305 | 201 (44.9) | 100 (51.3) | 0.134 |
Pain quality | 0.770 | 0.951 | ||||
Pulsating | 87 (64.5) | 40 (65.6) | 301 (68.1) | 128 (67.7) | ||
Pressing/tightening | 42 (31.1) | 17 (27.8) | 129 (29.2) | 55 (29.1) | ||
Other | 6 (4.4) | 4 (6.6) | 12 (2.7) | 6 (3.2) | ||
UAs | 55 (39.9) | 25 (39.7) | 0.982 | 219 (49.3) | 107 (56.3) | 0.107 |
Allodynia | 57 (41.3) | 32 (50.8) | 0.209 | 262 (58.6) | 121 (63.0) | 0.297 |
Dopaminergic symptoms | 95 (68.8) | 51 (81.0) | 0.074 | 297 (669) | 120 (63.5) | 0.409 |
UP + allodynia | 31 (47.0) | 24 (66.7) | 0.056 | 118 (53.6) | 88 (68.8) | 0.006 |
UP + UAs | 28 (43.1) | 26 (72.2) | 0.005 | 111 (50.7) | 83 (64.8) | 0.010 |
UP + UAs + allodynia | 26 (55.3) | 21 (65.6) | 0.360 | 96 (60.4) | 78 (75.0) | 0.014 |
Triptan responders | 93 (68.9) | 46 (7.0) | 0.554 | 252 (59.4) | 121 (66.8) | 0.085 |
Concomitant prophylaxis | 72 (54.5) | 33 (54.1) | 0.835 | 259 (58.6) | 100 (51.8) | 0.112 |
Prior treatment failures | 5.6 ± 3.2 | 5.2 ± 3.0 | 0.471 | 6.9 ± 3.4 | 7.0 ± 3.4 | 0.777 |
BoNT/A respondersa | 9 (18.3) | 6 (37.5) | 0.216 | 19 (8.7) | 4 (4.7) | 0.350 |
≥ 1 comorbidity | 74 (51.4) | 28 (43.7) | 0.386 | 213 (46.5) | 86 (43.4) | 0.522 |
Psychiatric comorbidities | 19 (13.7) | 9 (14.3) | 1.000 | 106 (23.6) | 40 (20.4) | 0.372 |
HIT-6 score | 64.9 ± 7.1 | 65.4 ± 5.4 | 0.657 | 66.3 ± 9.4 | 66.0 ± 11.0 | 0.754 |